SCHEMBL892319

SCHEMBL892319

Cc1ccc(-c2ncc(C(N)=O)s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.49
MAPT P10636 4/20 0.49
CDC7 O00311 1/20 0.49
DBF4 Q9UBU7 1/20 0.49
RAB9A P51151 8/20 0.47
NPC1 O15118 6/20 0.47
ALDH1A1 P00352 5/20 0.47
GSK3B P49841 1/20 0.47
PPARG P37231 2/20 0.46
NCOA2 Q15596 2/20 0.46
NCOA1 Q15788 2/20 0.46
NCOA3 Q9Y6Q9 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
HDAC1 Q13547 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4283912 0.85 HCAR2 (0.55) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL6604867 0.83 SMN1; SMN2 (0.69) SMN1; SMN2MAPTRAB9ANPC1ALDH1A1
SCHEMBL999672 0.83 GSK3B (0.49) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL27605413 0.83 SMN1; SMN2 (0.53) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL31341150 0.83 PTPN11 (0.58) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL892779 0.83 MAPT (0.68) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL12925920 0.83 SMN1; SMN2 (0.49) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL31341117 0.81 HSD17B1 (0.56) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL10848656 0.81 CDC7 (0.61) SMN1; SMN2MAPTCDC7DBF4RAB9A
SCHEMBL28794350 0.81 CDC7 (0.54) SMN1; SMN2MAPTCDC7DBF4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727546-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE The Global Alliance for TB Drug Development, Inc. (US) 2026-04-22 EP disclosed
WO-2025019626-A2 PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2025-01-23 WO disclosed
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN SMN1; SMN2 80/4885MAPT 2/4885CDC7 4140/4885
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases SNCA, MAPT, NLN SMN1; SMN2 80/4885MAPT 2/4885CDC7 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.